These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21572852)

  • 1. Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting.
    Kalyesubula R; Kagimu M; Opio KC; Kiguba R; Semitala CF; Schlech WF; Katabira ET
    Afr Health Sci; 2011 Mar; 11(1):16-23. PubMed ID: 21572852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients.
    Kumarasamy N; Venkatesh KK; Cecelia AJ; Devaleenal B; Lai AR; Saghayam S; Balakrishnan P; Yepthomi T; Poongulali S; Flanigan TP; Solomon S; Mayer KH
    AIDS Patient Care STDS; 2008 Apr; 22(4):337-44. PubMed ID: 18422462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
    Wit FW; Weverling GJ; Weel J; Jurriaans S; Lange JM
    J Infect Dis; 2002 Jul; 186(1):23-31. PubMed ID: 12089658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors of severe hepatotoxicity among HIV-1 infected individuals initiated on highly active antiretroviral therapy in the Northwest Region of Cameroon.
    Abongwa LE; Nyamache AK; Charles F; Torimiro J; Emmanuel N; Domkam I; Eyongetah M; Jude B; Mua FH; Bella S; Tamboh TC; Moungang EC; Ngum V; Okemo P
    BMC Gastroenterol; 2022 Jun; 22(1):286. PubMed ID: 35658835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients].
    Li WJ; Dai Y; Han Y; Qiu ZF; Xie J; Zuo LY; Li YL; Li TS
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(19):1318-22. PubMed ID: 21756757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
    Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
    Torti C; Lapadula G; Casari S; Puoti M; Nelson M; Quiros-Roldan E; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Mazzotta F; Lo Caputo S; Di Perri G; Filice G; Tinelli C; Carosi G;
    BMC Infect Dis; 2005 Jul; 5():58. PubMed ID: 16018804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa.
    Chu KM; Boulle AM; Ford N; Goemaere E; Asselman V; Van Cutsem G
    PLoS One; 2010 Feb; 5(2):e9183. PubMed ID: 20174653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
    Wu PY; Cheng CY; Liu CE; Lee YC; Yang CJ; Tsai MS; Cheng SH; Lin SP; Lin DY; Wang NC; Lee YC; Sun HY; Tang HJ; Hung CC
    PLoS One; 2017; 12(2):e0171596. PubMed ID: 28222098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
    Adedeji TA; Adebisi SA; Adedeji NO
    Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens.
    Jamisse L; Balkus J; Hitti J; Gloyd S; Manuel R; Osman N; Djedje M; Farquhar C
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):371-6. PubMed ID: 17259905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
    Mbougua JB; Laurent C; Kouanfack C; Bourgeois A; Ciaffi L; Calmy A; Gwet H; Koulla-Shiro S; Ducos J; Mpoudi-Ngolé E; Molinari N; Delaporte E
    BMC Public Health; 2010 Mar; 10():105. PubMed ID: 20193053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India.
    Sreenivasan S; Dasegowda V
    J Infect Dev Ctries; 2010 Nov; 4(11):750-3. PubMed ID: 21252454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.
    Manfredi R; Calza L; Chiodo F
    HIV Clin Trials; 2005; 6(6):302-11. PubMed ID: 16452064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India.
    Kumarasamy N; Vallabhaneni S; Cecelia AJ; Yepthomi T; Balakrishnan P; Saghayam S; Flanigan TP; Carpenter CC; Solomon S; Mayer KH
    J Acquir Immune Defic Syndr; 2006 Jan; 41(1):53-8. PubMed ID: 16340473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute liver enzyme elevations in HIV-1-infected patients.
    Livry C; Binquet C; Sgro C; Froidure M; Duong M; Buisson M; Grappin M; Quantin C; Portier H; Chavanet P; Piroth L
    HIV Clin Trials; 2003; 4(6):400-10. PubMed ID: 14628283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India.
    Sundaram M; Saghayam S; Priya B; Venkatesh KK; Balakrishnan P; Shankar EM; Murugavel KG; Solomon S; Kumarasamy N
    Int J Infect Dis; 2008 Nov; 12(6):e61-6. PubMed ID: 18621564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
    Torti C; Costarelli S; De Silvestri A; Quiros-Roldan E; Lapadula G; Cologni G; Paraninfo G; Castelnuovo F; Puoti M; Carosi G;
    Drug Saf; 2007; 30(12):1161-9. PubMed ID: 18035868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of liver and renal functions in human immunodeficiency virus-infected persons on highly active antiretroviral therapy: A mixed cohort study.
    Mahajan VK; Wadhwa D; Sharma A; Chauhan S; Vashist S; Kumar P; Chowdhry B
    Indian J Dermatol Venereol Leprol; 2020; 86(5):499-507. PubMed ID: 31975695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.